Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022

Annual recommendations on the use of influenza vaccine in Canada are developed by the NACI Influenza Working Group (IWG) for consideration by NACI. Recommendations are developed based on a review of a variety of issues, which can include: the burden of influenza illness and the target populations for vaccination; efficacy, effectiveness, immunogenicity, and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. In addition, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing their recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels. These programmatic factors include economics, ethics, equity, feasibility, and acceptability.

Données et ressources

Info additionnelle

Champ	Valeur
Dernière modification	avril 17, 2026, 21:20 (TU)
Créé le	avril 17, 2026, 21:20 (TU)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2021-05-31 00:00:00
open_canada_keywords	{"fr": ["vaccin", "grippe", "Comité", "consultatif", "national", "l’immunisation", "Une déclaration", "d'un comité consultatif", "DCC", "CCNI", "ARN", "Acide", "ribonucléique", "CDC", "Centers for Disease Control", "Prevention", "DIN", "Numéro", "d'identification", "médicament", "ECR", "Essai", "contrôlé", "randomisé", "ÉI", "Évènements", "indésirables", "ESSI", "EP", "Efficacité", "potentielle", "réelle", "Effet", "secondaire", "suivant", "GCI", "Guide", "canadien", "HAART", "HA", "Hémagglutinine", "Traitement", "antirétroviral", "hautement", "actif", "IC", "Intervalle", "confiance", "Ig", "Immunoglobuline", "IM", "Intramusculaire", "IMC", "Indice", "masse", "corporelle", "IMPACT", "Programme", "canadien", "surveillanc", "active", "de", "MGT", "Moyenne", "géométrique", "titres", "NA", "Neuraminidase", "OMS", "Organisation", "mondiale", "Santé", "PS", "Professionnel", "santé", "RMGT", "Rapport", "de la moyenne", "géométrique", "titres", "RRO", "Vaccin contre", "rougeole", "rubéole", "oreillons", "SCSESSI", "Système", "canadien", "surveillance", "SGB", "Syndrome", "Guillain-Barré", "SOR", "Syndrome", "oculo-respiratoire", "TNDN", "Troubles", "neurologiques", "développement", "neurologique", "TS", "Travailleur", "santé", "UFF", "Unité", "foyers", "fluorescents", "VII", "Vaccin", "inactivé", "contre", "l'influenza", "VII3", "Vaccin trivalent", "inactivé", "contreVII3-Adj", "Vaccin", "inactivé", "contre", "adjuvant", "VII3-SD", "Vaccin", "trivalent", "inactivé", "contre", "dose", "standard", "VII3-HD", "trivalent", "contre", "haute", "VII4", "quadrivalent", "VII4-SD", "VIH", "Virus", "immunodéficience", "humaine", "VRZ", "recombinant", "zona", "VVAI", "vivant", "atténué", "VVAI3", "atténué", "VVAI4"], "en": ["Influenza", "vaccine", "National", "Advisory", "Committee", "Immunization", "Adverse", "event", "AEFI", "CAEFISS", "Canadian", "Adverse", "Events", "Following", "Immunization", "Surveillance", "System", "CI", "Confidence", "interval", "CIG", "Canadian", "Guide", "DIN", "Drug", "Identification", "Number", "FFU", "Fluorescent", "focus", "units", "GBS", "Guillain-Barré", "syndrome", "GMT", "Geometric", "mean", "titre", "GMTR", "Geometric", "ratio", "HA", "Hemagglutinin", "HAART", "Highly", "active", "antiretroviral", "therapy", "HCW", "Health", "care", "worker", "HIV", "Human", "immunodeficiency", "virus", "Ig", "Immunoglobulin", "IIV", "Inactivated", "IIV3", "Trivalent", "inactivated", "IIV3-Adj", "Adjuvanted", "IIV3-HD", "High-dose", "trivalent inactivated", "IIV3-SD", "Standard-dose", "IIV4", "Quadrivalent", "inactivated", "IIV4-SD", "Standard-dose", "ILI", "Influenza-like", "illness", "IM", "Intramuscular", "Immunization", "Monitorin", "Program", "Active", "LAIV", "Live", "attenuated", "LAIV3", "Trivalent", "live", "attenuated", "LAIV4", "Quadrivalent", "MMR", "Measles", "mumps", "rubella", "NA", "Neuraminidase", "NACI ORS", "Oculorespiratory", "syndrome", "RCT", "Randomized", "controlled", "trial", "RNA", "Ribonucleic acid", "RZV", "Recombinant", "zoster", "vaccine", "SAE", "Serious", "adverse", "event", "VE", "Vaccine", "effectiveness", "WHO", "World Health", "Organization", "Advisory", "Committee", "Statement", "ACS", "IMPACT"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur la vaccination antigrippale pour la saison 2021-2022
update_frequency	unknown